Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology
MHA Jansen, DG Van Vuurden, WP Vandertop… - Cancer treatment …, 2012 - Elsevier
MHA Jansen, DG Van Vuurden, WP Vandertop, GJL Kaspers
Cancer treatment reviews, 2012•ElsevierPatients with diffuse intrinsic pontine gliomas (DIPG) have a poor prognosis. Although DIPG
constitute only 10–15% of all pediatric brain tumors, they are the main cause of death in this
group. Despite 26 clinical trials in newly diagnosed DIPG in the past 5years (including
several targeted agents), there is no clear improvement in prognosis. However, knowledge
on DIPG biology is increasing, mainly due to the (re) introduction of biopsies and autopsies,
the possibility of gene expression profiling, and the development of in vivo models …
constitute only 10–15% of all pediatric brain tumors, they are the main cause of death in this
group. Despite 26 clinical trials in newly diagnosed DIPG in the past 5years (including
several targeted agents), there is no clear improvement in prognosis. However, knowledge
on DIPG biology is increasing, mainly due to the (re) introduction of biopsies and autopsies,
the possibility of gene expression profiling, and the development of in vivo models …
Patients with diffuse intrinsic pontine gliomas (DIPG) have a poor prognosis. Although DIPG constitute only 10–15% of all pediatric brain tumors, they are the main cause of death in this group. Despite 26 clinical trials in newly diagnosed DIPG in the past 5years (including several targeted agents), there is no clear improvement in prognosis. However, knowledge on DIPG biology is increasing, mainly due to the (re)introduction of biopsies and autopsies, the possibility of gene expression profiling, and the development of in vivo models. Translation of this knowledge into clinical trials in combination with improved drug distribution methods may eventually lead to more effective treatment of this devastating disease.
Elsevier